factor xiii deficiency occurs exceedingly rarely causing severe bleeding tendency incidence one million one five million people higher incidence areas consanguineous marriage iran highest global incidence due mutations subunit gene located chromosome mutation inherited autosomal recessive fashion deficiency factor xiii leads defective crosslinking fibrin vulnerability late rebleeds primary hemostatic plug overwhelmed bleeding tendencies similar hemophiliacs develop hemarthroses deep tissue bleeding factor xiii composed two subunit protein b genes located different chromosomes administration recombinant subunit improves clot stability becoming therapeutic option patients bleeding manifestation normal pt aptt tt bt ct suspected factor xiii deficiency confirmatory test urea lysis test clot easily lysed urea solution unstable clot factorxiii deficiency confirmedcitation needed fresh frozen plasma cryoprecipitate mainstay therapy factor xiii deficiency carry risk related transfusioncitation needed two commercially produced factor xiii concentrates currently available europe one manufactured bio products laboratory bpl available united kingdom fibrogamminp produced beringwerke germany us fxiii concentrate available federal drug administrations investigational new drug ind program clinical recombinant factor xiii rfxiii drug alternative receiving blood transfusions traditional treatment factor xiii deficiency novo nordisk rfxiii catridecacog approved us food drug administration although recombinant protein rfxiii subunit identical structure function subunit factor xiii naturally produced body healthy patients need exogenous subunit factor xiii since mutation prevents production subunit however since bsubunit located separate chromosome factor xiii deficient patients actually produce bsubunit normally two subunits interact plasma enzyme activated act within clotting rfxiii acts inhibiting fibrinolysis factors enzymatically cleave fibrin matrix leading ultimate formation clotscitation needed rfxiii synthetically bioengineered yeast expression system administered intravenously clinical trials drug administered every four weeks administered ondemand order treat bleeding introduction rfxiii treatment factor xiii deficiency eliminates risk pathogenic infection present plasmabased treatments rfxiii treatment would also dependent blood donations consequently increasing availability product quality one biggest fears developing rfxiii body would mount immuneresponse protein however several safety pharmacokinetics studies reported immunogenic response rfxiii associated yeast httpsenwikipediaorgwikifactorxiiideficiency